Press ReleaseView printer-friendly version
Materialise and University of Michigan Sign License Agreement for Life-Saving, 3D-Printed Tracheal Splints
Collaboration opens the door for technology to help more infants diagnosed with life-threatening tracheobronchomalacia (TBM).
Today, Materialise (NASDAQ:MTLS), has entered into an exclusive
licensing arrangement with the
About 1 in 2,200 babies are born with TBM, which causes the trachea to periodically collapse. The tracheal splint, developed to save the lives of these children, is made with a biopolymer called polycaprolactone, a biodegradable material that is gradually absorbed into the infant’s body tissue over time.
“Here at Materialise, we strongly believe in the transformative power
of great collaborations, such as the one we have enjoyed these past two
years with Dr. Green, Dr. Hollister, and all others who have contributed
to this live-saving application of 3D printing,” stated
Founder and CEO of Materialise, Fried Vancraen, added, “It was the
possibility to realize 3D-printing enabled medical applications that, in
part, motivated me to start Materialise 25 years ago. Today, we are
proud to offer an entire range of software and services that can help
universities, research centers, medical device companies, and hospitals
develop solutions that result in a better and healthier world, such as
the treatment developed for children diagnosed with TBM. It has been an
honor to work with the team at
“This agreement is a critical step in our goal to make this treatment
readily available for other children who suffer from this debilitating
condition,” Mott otolaryngologist Dr.
“We have continued to evolve and automate the design process for the
splints, allowing us to achieve in two days what used to take us up to
five days to accomplish,” adds
The U-M team hopes to next year open a clinical trial for 30 patients with similar conditions at C.S. Mott Children’s Hospital.
With its headquarters in Leuven,
About C.S. Mott Children’s Hospital
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements regarding, among other things, the plans, objectives, expectations, strategies and prospects of the Company, both financial and business. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will”, “may”, “could”, “might”, “aim”, “should” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the management’s current expectations. These expectations, beliefs and projections are given in good faith and management believes there is a reasonable basis for them. However, the management cannot offer any assurance that its expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Management cautions readers that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. All of the forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations. Management makes no commitment, and disclaims any duty to update or revise any forward-looking statements to reflect future events or changes in its expectations.
Corporate Communications Specialist, Materialise
Phone: +32 16 39 66 37
Fax: +32 16 39 66 00
Twitter: @belgiancanuck or @MaterialiseNV